Feeds:
Posts
Comments

Posts Tagged ‘Fibromyalgia’

The Wall Street Journal (2/24, Dorman) reported, “Pfizer Inc. has ended development of two late-stage drugs, as part of its previously stated strategy to allocate resources to higher-potential efforts, including pursuing additional uses for its blockbuster fibromyalgia drug Lyrica [pregabalin].” One of the medications, esreboxetine, “was…developed to treat fibromyalgia and the other [known as PD 332,334] was one for generalized anxiety disorder.” Pfizer “will continue to pursue Lyrica as a treatment for generalized anxiety disorder.” According to the AP (2/25, Johnson), “Neither compound had been seen as a likely blockbuster because other drugs to treat those conditions already are on the market.” The company “said it reviewed results from the first late-stage study for PD 332,334 and all the data for esreboxetine, ‘along with current market dynamics,’ before making the decision.” Pedro Lichtinger, president and general manager of Pfizer’s Primary Care Business Unit, said that “‘while confident in the safety of these compounds, we don’t believe that they provide significant benefit over other therapies’ on the market.”

Read Full Post »

Bloomberg News (1/14, Lopatto) reports that, according to a study published in the Jan. 14 issue of the Journal of the American Medical Association, “Certain antidepressants lessen the distress of pain and sleep disturbances for fibromyalgia patients, boosting their quality of life.” Winfried Hauser, M.D., of the Klinikum Saarbruecken, and colleagues, conducted a meta-analysis of “18 randomized trials, with a combined 1,427 participants.”
        WebMD (1/13, Boyles) noted that the trials contained “patients taking different classes of antidepressants, including low doses of tricyclic and tetracyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRI), and monoamine oxidase inhibitors (MAOIs).” Using “a standardized model to assess the effectiveness of the medications on common fibromyalgia symptoms,” researchers found that the “TCA amitriptyline (Elavil, Endep), given in low doses, had the largest effect on pain, fatigue, and sleep disturbances. Little effect was recorded on depressed mood, however.”
        Based on their findings, the investigators wrote that “since evidence for a long-term effect of antidepressants in [fibromyalgia] is still lacking, their effects should be re-evaluated at regular intervals to determine whether benefits outweigh adverse effects,” HealthDay (1/13, McKeever) reported.
        The condition “affects up to 12 million people (four percent of the U.S. population), nearly 11 million of them women,” Scientific American (1/13, Ballantyne) added. Experts say that the “degree of debilitation caused by the disease ranges ‘from very little to total.'” At present, “there is no definitive test for fibromyalgia, which doctors typically diagnose based on symptoms, including chronic widespread pain.”

Read Full Post »

In the Los Angeles Times (11/3) Booster Shots blog, Melissa Healy wrote that, although “the pain that is the hallmark of the condition called fibromyalgia doesn’t show up on images and scans of muscle and bone,” it can be detected using Single Positron Emission Computed Tomography (SPECT) imaging, according to a study published in the Nov. issue of the Journal of Nuclear Medicine. The technology “allows precise measurements of blood flow to different parts of the brain — and hence, of electrical activity.” In the study, “SPECT imaging revealed significant differences in the brain function of 20 women diagnosed with fibromyalgia and 10 healthy women used as controls.” WebMD (11/3, Wilbert) and HealthDay (11/3, Doheny) also covered the story.

Read Full Post »